Most Read Articles
Natalia Reoutova, 4 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

Family history of melanoma ups risk of melanoma, keratinocyte cancers

29 Jul 2019

Individuals who have a first-degree relative with melanoma are at an increased risk of melanoma and keratinocyte cancers (KCs), according to a study.

The investigators prospectively followed 216,115 participants from the Nurses’ Health Study, Nurse’s Health Study 2 and Health Professionals Follow-up Study for more than 20 years to determine the risk of melanoma and KCs in those with a positive family history of melanoma.

The association between family history of melanoma and melanoma and KCs was estimated using Cox proportional hazards regression, controlling for known pigmentary and environmental risk factors for skin cancer.

Individuals with a family history of melanoma had a 74-percent higher risk of melanoma (hazard ratio [HR], 1.74, 95 percent CI, 1.45–2.09), a 22-percent higher risk of squamous cell carcinoma (SCC; HR, 1.22, 1.06–1.40) and 27-percent higher risk of basal cell carcinoma (BCC; HR, 1.27, 1.12–1.44) than those without.

Family history of melanoma heightened the risk of developing truncal melanoma in both sexes, as well as extremity melanoma and extremity squamous cell carcinoma in women.

An earlier study by Wu and colleagues reported an association between personal history of KC and an increased risk of melanoma. This association was more pronounced among individuals with a history of both BCC and SCC (HR, 3.40, 1.60–7.19) than among those with a history of BCC only (HR, 2.20, 1.80–2.70) or SCC only (HR, 1.56, 0.98–2.46). [J Natl Cancer Inst 2017;doi:10.1093/jnci/djw268]

The current study was limited by self-reported family history and detection bias, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 4 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).